Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 16612599 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| and autologous dc of hla-a*0201(+) patients with hormone-refractory prostate cancer were loaded with antigenic peptides derived from prostate stem cell antigen (psca(14-22)), prostatic acid phosphatase (pap(299-307)), prostate-specific membrane antigen (psma(4-12)), and prostate-specific antigen (psa(154-163)). | |||||||
| 16937115 | HLA-A*03 | prostate cancer | NA | NA | NA | only_studied | |
| identification of sart3-derived peptides having the potential to induce cancer-reactive cytotoxic t lymphocytes from prostate cancer patients with hla-a3 supertype alleles. | |||||||
| 16937115 | HLA-A*24 | prostate cancer | NA | NA | NA | only_studied | |
| sart3-derived peptides applicable to prostate cancer patients with hla-a3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the hla-a2 and hla-a24 alleles. | |||||||
| 16937115 | HLA-A*03 | prostate cancer | NA | NA | NA | only_studied | |
| sart3-derived peptides applicable to prostate cancer patients with hla-a3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the hla-a2 and hla-a24 alleles. | |||||||
| 16937115 | HLA-A*33 | prostate cancer | NA | NA | NA | unclassified | |
| twenty-nine sart3-derived peptides that were prepared based on the binding motif to the hla-a3 supertype alleles (hla-a11, -a31, and -a33) were first screened for their recognizability by immunoglobulin g (igg) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic t lymphocytes (ctls) from hla-a3 supertype(+) prostate cancer patients. | |||||||
| 16937115 | HLA-A*11 | prostate cancer | NA | NA | NA | unclassified | |
| twenty-nine sart3-derived peptides that were prepared based on the binding motif to the hla-a3 supertype alleles (hla-a11, -a31, and -a33) were first screened for their recognizability by immunoglobulin g (igg) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic t lymphocytes (ctls) from hla-a3 supertype(+) prostate cancer patients. | |||||||
| 16937115 | HLA-A*31 | prostate cancer | NA | NA | NA | unclassified | |
| twenty-nine sart3-derived peptides that were prepared based on the binding motif to the hla-a3 supertype alleles (hla-a11, -a31, and -a33) were first screened for their recognizability by immunoglobulin g (igg) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic t lymphocytes (ctls) from hla-a3 supertype(+) prostate cancer patients. | |||||||
| 16937115 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| twenty-nine sart3-derived peptides that were prepared based on the binding motif to the hla-a3 supertype alleles (hla-a11, -a31, and -a33) were first screened for their recognizability by immunoglobulin g (igg) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic t lymphocytes (ctls) from hla-a3 supertype(+) prostate cancer patients. | |||||||
| 16937115 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| these results indicate that these two sart3 peptides could be promising candidates for peptide-based immunotherapy for hla-a3 supertype(+) prostate cancer patients. | |||||||
| 17440952 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| ten human leukocyte antigen (hla)-a24(+) patients with localized prostate cancer received weekly personalized peptide vaccine for six times with positive peptides (up to four kinds of peptides) from 16 kinds of vaccine candidates, followed by a retropubic radical prostatectomy (rrp). | |||||||
Copyright 2024